LCN2 and breast cancer: HIC1 expression has been found to be silenced only in triple-negative breast cancer compared with other breast cancer molecular subtypes, and HIC1 slicing could facilitate triple-negative breast cancer progression by targeting lipocalin-2 (LCN2) (32).